We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Celera and LabCorp® Announce Agreement to Commercialize Breast Cancer Testing Essays
News

Celera and LabCorp® Announce Agreement to Commercialize Breast Cancer Testing Essays

Celera and LabCorp® Announce Agreement to Commercialize Breast Cancer Testing Essays
News

Celera and LabCorp® Announce Agreement to Commercialize Breast Cancer Testing Essays

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Celera and LabCorp® Announce Agreement to Commercialize Breast Cancer Testing Essays"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Celera, an Applera Corporation business, and Laboratory Corporation of America® Holdings (LabCorp®) announced that they have signed an agreement granting LabCorp a license to Celera's breast cancer metastasis and estrogen/progesterone receptor discoveries.

The license agreement allows LabCorp to select from among Celera's genomic findings to develop and commercialize two molecular oncology laboratory service tests.

LabCorp plans to offer one test to help predict the risk of metastasis in early stage breast cancer patients, and a second test to provide a molecular assessment of hormonal receptor status, which is used to select women for endocrine therapy.

The tests that LabCorp plans to offer based on Celera's findings may provide information that is distinct from that predicted by routine clinical assessment tools, such as tumor grade, as well as quantify risk for metastasis for variable time periods rather than only categorically for five or 10 years.

Many of the discoveries licensed to LabCorp under this agreement are involved in the p53 tumor suppressor signaling pathways and are implicated in cancer proliferation.

Under the terms of the agreement, LabCorp will pay Celera an up-front license fee and royalties on net sales of laboratory service tests performed by LabCorp that incorporate Celera's discoveries. Further financial details were not disclosed.

"This license agreement with Celera strategically complements our innovative and extensive pipeline of diagnostic services and reinforces our strong commitment to genetic and molecular oncology testing," said Myla P. Lai-Goldman, M.D., Executive Vice President, Chief Scientific Officer and Medical Director of LabCorp.

"Applying Celera's findings in breast cancer to the development of new tests supports our ever-growing menu of esoteric and genomic tests, and underscores our commitment to bring relevant clinical tests to market," Lai-Goldman further said.

"We are pleased to have entered into this agreement with LabCorp, which has a track record of introducing new testing services that improve patient management," said Kathy Ordonez, President of Celera.

"LabCorp shares our belief that Celera's breast cancer discoveries could have a beneficial effect on hundreds of thousands of women living with the uncertainty of breast cancer recurrence," Ordonez added.

Advertisement